NOVO-AZT CAP 100MG 100 MG
ZIDOVUDINE : 100 MG · DIN 01953877 · NOVOPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is NOVO-AZT CAP 100MG?
NOVO-AZT CAP 100MG 100 MG contains ZIDOVUDINE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 01953877, held by NOVOPHARM LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 26-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01953877 |
|---|---|
| Brand name | NOVO-AZT CAP 100MG |
| Generic / active ingredient | ZIDOVUDINE : 100 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | 100 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AF01 ZIDOVUDINE |
| AHFS class | 08:18.08.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 26-Oct-2015 |
| Original market date | 1992-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J05AF01 ZIDOVUDINE. 3 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ZIDOVUDINE | 100 MG | CAPSULE | APOTEX INC | MARKETED | DIN 01946323 |
| RETROVIR (AZT) | 10 MG | SOLUTION | VIIV HEALTHCARE ULC | MARKETED | DIN 01902644 |
| RETROVIR (AZT) | 50 MG / 5 ML | SYRUP | VIIV HEALTHCARE ULC | MARKETED | DIN 01902652 |
| RETROVIR (AZT) | 100 MG | CAPSULE | VIIV HEALTHCARE ULC | CANCELLED POST MARKET | DIN 01902660 |
| RETROVIR (AZT) 300MG | 300 MG | TABLET | GLAXO WELLCOME INC. | CANCELLED POST MARKET | DIN 02238699 |
| ZIDOVUDINE ORAL SOLUTION USP | 50 MG / 5 ML | SOLUTION | AUROBINDO PHARMA LIMITED (UNIT III) | APPROVED | DIN 02282186 |
Who else supplies ZIDOVUDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ZIDOVUDINE appears in 1364 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.